Stockreport

Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet

Biohaven Ltd. Common Shares  (BHVN) 
Last biohaven ltd. common shares earnings: 2/25 04:45 pm Check Earnings Report
US:NYSE Investor Relations: investors.biohavenpharma.com